Acta Scientific Cancer Biology (ASCB) (ISSN: 2582-4473)

Research Article Volume 6 Issue 7

Diagnosis and Follow-up of Non-Hodgkin Lymphoma in Dakar, Senegal

Niang EHD1,2*, Faye BF1,3, Fall S1,2, Seck M1,3, Touré SA1,3, Sarr K1,2, Ndiaye FSD1,2 and Diop S1,3

1Cheikh Anta Diop University-Hematology, Dakar, Senegal
2Dalal Jamm Hospital, Hematology Clinic Department, Dakar, Senegal
3National Blood Transfusion Center, Hematology Clinic Department, Dakar, Senegal

*Corresponding Author: Niang EHD, Cheikh Anta Diop University-Hematology, Dakar, Senegal.

Received: January 31, 2022; Published: November 30, 2022



The management of Non-Hodgkin Lymphoma (NHL) in Senegal is challenging due to the lack of exploration tools and the inaccessibility of anticancer drugs. This study aimed to identify the prognostic factors at diagnosis and to assess their outcome under treatment.


We conducted a descriptive and analytical prospective study range from 1st January 2018 to 3rd July 2020 covering NHL cases. Initial prognostic factors were assessed according to the International Prognostic Index for diffuse large cell B lymphoma and T-cell lymphoma, the Mantle Cell Lymphoma International Prognostic Index and the Follicular Lymphoma International Index for mantle cell lymphoma and small cell lymphoma respectively. B-cell lymphomas were treated with polychemotherapy with or without rituximab, T-cell lymphomas were treated with polychemotherapy alone. Progression was assessed on the basis of response to treatment, toxicity and survival.


We included 40 patients, 30 males and 10 females with a sex ratio of 3. The mean age was 43.38 years +15.87. The mean time from symptom onset to diagnostic confirmation was 7.4 months. The total follow-up time of the cohort was 30.5 patient-years. B-cell lymphomas accounted for 57.5% of cases, T-cell lymphomas for 27.5% of cases. Twenty-five patients (67.6% of cases) were at an advanced stage at diagnosis. The initial prognosis was unfavourable in 29.7% of cases, all histological types combined. The overall survival at 30 months was 70%.


Our patients were diagnosed with advanced disease stage. The overall survival at 30 months was short. Early diagnosis and better access to immunochemotherapy could improve these results.

Keywords: Non-Hodgkin lymphoma; Diagnosis; Prognosis; Treatment; Africa


  1. Ndiaye F., et al. “Prognostic factors of non-hodgkin lymphoma: retrospective study in unit blood service of the internal medicine dantec in dakar (senegal)”. Open Journal of Hematology (2015).
  2. “13 Various hemopathies and methods of study”. Haematology1 (2018): 145-157.
  3. Diop S., et al. “[Non-Hodgkin’s lymphoma in Dakar: study of 107 cases diagnosed between 1986 and 1998]”. Bulletin de la Société de Pathologie Exotique 2 (2004): 109‑112.
  4. Oyekunle AA., et al. “Factors determining survival in Nigerian patients with lymphoma”. Blood Reviews1 (2007): 131-132.
  5. Evans LS and Hancock BW. “Non-Hodgkin lymphoma”. The Lancet 362 (2003): 139-146.
  6. Miller TP and Jones SE. “Initial chemotherapy for clinically localized lymphomas of unfavorable histology”. Blood2 (1983): 413-418.
  7. Coiffier B. “Prognostic factors in non-Hodgkin lymphomas-therapeutic implications”. Revue du praticien 13 (1993): 1640-1643.
  8. Casulo C., et al. “Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Study†”. Annals of Oncology 11 (2015): 2311‑2317.
  9. Thiam D., et al. “Epidemiology and therapy of malignant hemopathies in Senegal”. Hematology, Transfusion and Cell Therapy2 (1996): 187‑191.
  10. Tolo A., et al. “Epidemiological, clinical and evolutionary profile of malignant non-Hodgkin lymphomas (non-burkitt) in black Africans”. Medicine Afr Noire (1999): 4.
  11. Sawadogo D., et al. “Study of some prognostic factors for non-Burkitt non-Hodgkin malignant lymphomas in urban tropical areas in Côte d'Ivoire”. Black African Medicine7 (2001): 295-299.
  12. , et al. “CHOP Chemotherapy for Aggressive Non Hodgkin Lymphoma with and without HIV in the Antiretroviral Therapy Era in Malawi”. Plos One (2016).
  13. Keegan TH., et al. “Improvements in survival after follicular lymphoma by race/ethnicity and socioeconomic status: a population-based study”. Journal of Clinical Oncology 18 (2009): 3044-3051.


Citation: Niang EHD., et al. “Diagnosis and Follow-up of Non-Hodgkin Lymphoma in Dakar, Senegal" Acta Scientific Cancer Biology 6.7 (2022): 14-18.


Copyright: © 2022 Niang EHD., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Acceptance rate35%
Acceptance to publication20-30 days
Impact Factor1.183

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is June 25, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US